Skip to main content

Table 5 Immunotherapeutic aptamers

From: Aptamers as an approach to targeted cancer therapy

Aptamer name

Type

Target

RNA or DNA

Modification

Function

Refs.

RNA Aptamer

Antagonistic

CTLA-4

RNA

–

Inhibition of CTLA-4 functions and enhance tumor immunity in cell and animal models

[124]

aptCTLA-4

Antagonistic

CTLA-4

DNA

–

Promotes lymphocyte proliferation, and inhibits tumor growth in both in vitro and in vivo

[125]

CTLA4apt–STAT3 siRNA

Antagonistic

CTLA-4

RNA

Covalently linked to a STAT-3 siRNA

STAT-3 gene silencing in CD8+ infiltrated lymphocytes and regulatory T cells (Tregs) in tumors and subsequently inhibits tumor growth and metastasis

[126]

MP7

Antagonistic

PD-1

DNA

Conjugated to the polyethylene glycol (PEG)

Inhibits the suppression of IL-2 secretion in primary T-cells and suppresses the tumor growth

[127]

aptPD-L1

Antagonistic

PD-L1

DNA

–

Stimulate lymphocyte proliferation in vitro, suppress tumor growth in vivo, and increase in the levels of infiltrating CD4+ and CD8+ T cells, as well as the cytokines IL-2, TNF-α, IFN-γ and the C-X-C motif chemokines

[128]

BSA-Apt

Antagonistic

PD-L1

DNA

Conjugated to the bovine serum albumin

Stronger antitumor efficacy

[129]

TIM-3 aptamer

Antagonistic

TIM-3

DNA

Trimeric form of the TIM-3 aptamer

Reduced cell death, and enhanced survival, proliferation, and cytokine secretion in vitro

[130]

LAG3 aptamer

Antagonistic

LAG3

RNA

2′-fluoro-pyrimidines

Enhances the threshold of T-cell activation

[131]

4-1BB aptamer

Agonistic

4-1BB

RNA

Bivalent and multivalent

Stimulate CD8+ T cells and inhibit tumor growth

[132]

4-1BB bispecific aptamer

Agonistic

4-1BB

RNA

2′-fluoro-pyrimidine, conjugated with vascular endothelial growth factor or osteopontin

Enhances the therapeutic index of tumor immunotherapy

[133]

hOX40 aptamer

Agonistic

OX40

RNA

2′-fluoro-pyrimidine and multimerized

Induce proliferation and IFN-γ production in activated human T cells in vitro

[134]

CD40 agonist aptamers

Agonistic

CD40

RNA

2ʹ-fluoropyrimidine

Hastened the improvement of bone marrow aplasia by inducing the reproduction and activation of B cells

[135]

CD40-blockade aptamer

Antagonist

CD40

RNA

2ʹ-fluoropyrimidine

Have a direct antitumor effect on CD40-expressing B-cell lymphoma in vitro and in vivo

[135]

CD40 agonistic aptamer-shRNA chimera

Agonistic

CD40

RNA

2ʹ-fluoropyrimidine, and linked with a short hairpin RNA targeting serine/threonine protein kinase

Enhancing tumor antigenicity by NMD inhibition and improvement in tumor infiltration and overall survival in vivo

[135]

CD28Apt2 and CD28Apt7

Agonistic

CD28

RNA

2ʹ-fluoropyrimidine and dimerization

Increasing the cellular immune system response and prolong the survival of mice

[136]

X-polymers

Antagonistic and Agonistic

CTLA-4 and CD28

RNA

CAR-like multivalent aptamer nanoparticles

Increase T cell proliferation and reverse the inhibitory effect of IL-2, and suppress the growth of mouse melanoma B16 cells both in vitro and in vivo

[137]

APT-β1

Inhibitors of immunosuppressive cytokines

TGF-β1

RNA

Combined with gefitinib

Enhanced the anti-tumor effect, and inhibit the regrowth of lung cancer

[138]

R5A1 aptamer

Inhibitors of immunosuppressive cytokines

IL-10 receptor

RNA

–

Inhibit CT26 tumor growth in mice

[123]